These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 21518838)
1. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838 [TBL] [Abstract][Full Text] [Related]
2. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Bhalodi AA; Crandon JL; Williams G; Nicolau DP Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330 [TBL] [Abstract][Full Text] [Related]
3. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates. Housman ST; Keel RA; Crandon JL; Williams G; Nicolau DP Antimicrob Agents Chemother; 2012 May; 56(5):2576-80. PubMed ID: 22330908 [TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. MacVane SH; Crandon JL; Nichols WW; Nicolau DP Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999 [TBL] [Abstract][Full Text] [Related]
7. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Keel RA; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Louie A; Castanheira M; Liu W; Grasso C; Jones RN; Williams G; Critchley I; Thye D; Brown D; Vanscoy B; Kulawy R; Drusano GL Antimicrob Agents Chemother; 2012 Jan; 56(1):258-70. PubMed ID: 22024819 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411 [TBL] [Abstract][Full Text] [Related]
11. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. MacGowan A; Tomaselli S; Noel A; Bowker K J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276 [TBL] [Abstract][Full Text] [Related]
12. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066 [TBL] [Abstract][Full Text] [Related]
13. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. Stachyra T; Levasseur P; Péchereau MC; Girard AM; Claudon M; Miossec C; Black MT J Antimicrob Chemother; 2009 Aug; 64(2):326-9. PubMed ID: 19493866 [TBL] [Abstract][Full Text] [Related]
15. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2015 May; 59(5):2688-94. PubMed ID: 25712356 [TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Wiskirchen DE; Nordmann P; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2014; 58(3):1671-7. PubMed ID: 24379195 [TBL] [Abstract][Full Text] [Related]
17. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Craig WA; Andes DR Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659 [TBL] [Abstract][Full Text] [Related]
18. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182 [TBL] [Abstract][Full Text] [Related]